PetVivo Holdings, Inc. has entered into an Exclusive License and Supply Agreement with VetStem, Inc. to commercialize VetStem’s innovative allogeneic orthobiologic products, PrecisePRP® canine and PrecisePRP® equine. This agreement marks a significant expansion of PetVivo's product offerings in regenerative medicine.
PrecisePRP® is a first-in-class, off-the-shelf platelet-rich plasma (PRP) product designed for veterinarians, eliminating the need for blood draws or centrifugation. Each vial guarantees a consistent dose of 4 billion platelets per vial at a concentration of 500,000 platelets per microliter.
Safety studies conducted in dogs and horses, at the request of the FDA, reported no treatment-related adverse events after administration of PrecisePRP®. This product is expected to be a valuable addition to PetVivo's portfolio, complementing Spryng with OsteoCushion Technology and supporting the company's leadership in veterinary medical devices.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.